Note 10. Share-based Compensation:

During the nine months ended March 31, 2023 and 2022, the Company granted 2.3 million and 1.4 million stock options at weighted average grant prices of $93.96 and $120.17 and weighted average fair values of $29.58 and $29.77, respectively. During the nine months ended March 31, 2023 and 2022, the Company granted 90,352 and 110,292 restricted stock units at a weighted average fair value of $93.84 and $117.59, respectively. During the nine months ended March 31, 2023 and 2022, the Company granted 10,816 and 27,584 shares of restricted common stock shares at a weighted average fair value of $73.94 and $122.34.

Stock options for 1,271,338 and 2,220,412 shares of common stock with total intrinsic values of $74.1 million and $196.3 million were exercised during the nine months ended March 31, 2023 and 2022, respectively.

Stock-based compensation expense, inclusive of payroll taxes, of $10.2 million and $8.7 million was included in selling, general and administrative expenses for the quarter ended March 31, 2023 and 2022, respectively. Stock-based compensation expenses, inclusive of payroll taxes, of $41.5 million and $35.9 million was included in selling, general, and administrative expenses for the nine months ended March 31, 2023 and 2022, respectively. Additionally, the company recognized $0.2 million and $0.8 million of stock-based compensation costs in cost of goods sold in the quarter and nine months ended March 31, 2023 respectively, compared to $0.4 million and $1.1 million in cost of goods sold in the comparative prior year periods. As of March 31, 2023, there was $44.1 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock. The weighted average period over which the compensation cost is expected to be recognized is 1.9 years.

​

In fiscal 2015, the Company established the Bio-Techne Corporation 2014 Employee Stock Purchase Plan (ESPP), which was approved by the Company's shareholders on October 30, 2014, and which is designed to comply with IRS provisions governing employee stock purchase plans. 800,000 shares were allocated to the ESPP. The Company recorded expense of $0.1 million for the quarter ended March 31, 2023 and immaterial expense for the quarter ended March 31, 2022. The Company recorded expense of $0.5 million and $0.6 million for the ESPP for the nine months ended March 31, 2023 and 2022, respectively.